China NT Pharma Group Proposed $100 Million For The Acquisition Of Hong Kong WD Pharmaceutical

On July 10, China NT Pharma Group just announced propose to use 100 million dollars to purchase 52% of issued stocks from Hong Kong WD Pharmaceutical, becoming the controlling shareholder of Hong Kong WD Pharmaceutical.

China NT Pharma Group plans to issue 427 million new shares to purchase the shares from Hong Kong WD Pharmaceutical. Hong Kong WD Pharmaceutical was founded in 2015, its main goal is to develop new medicines delivery system, it's 505(b)(2) new medicines delivery system has a short product development cycle, low investment and high development success rate. At this moment, China NT Pharma Group has 5 delivery system which is: UGI-Pump, AcuSIS, ABEDS, SELS and GI-pump.

At the same time, Hong Kong WD Pharmaceutical has 11 production lines, among them, the three products treated Parkinson has the best advantages on the market, Hong Kong WD Pharmaceutical's products can improve drug treatment benefits and reduce side effects to improve Parkinson patient's lives.